Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li1, Shukui Qin2, Ruihua Xu3, Thomas C C Yau4, Brigette Ma5, Hongming Pan6, Jianming Xu7, Yuxian Bai8, Yihebali Chi9, Liwei Wang10, Kun-Huei Yeh11, Feng Bi12, Ying Cheng13, Anh Tuan Le14, Jen-Kou Lin15, Tianshu Liu16, Dong Ma17, Christian Kappeler18, Joachim Kalmus18, Tae Won Kim19
1Department of Medical Oncology, Fudan University Shanghai Cancer Center and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
2Department of Medical Oncology, Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China
3Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
4Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China
5Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China
6Medical Oncology, Sir Run Run Shaw Hospital Medical School, Zhejiang University, Hangzhou, China
7Beijing 307 People's Liberation Army Hospital Cancer Centre, Beijing, China
8Third Affiliated Hospital of Harbin Medical University, Harbin, China
9Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
10Comprehensive Cancer Center, Shanghai First People's Hospital, Shanghai Jiaotong University, Shanghai, China
11Department of Oncology, National Taiwan University Hospital Taipei, Taiwan
12Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China
13Jilin Provincial Tumor Hospital, Changchun, China
15Department of Surgery, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan
16Department of Medical Oncology, Zhong Shan Hospital, Fudan University, Shanghai, China
17Department of Medical Oncology, Guangdong General Hospital, Guangzhou, Guangdong, China
18Bayer Pharma AG, Berlin, Germany
19Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, South Korea
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Oncology
Tập 16
619-629
Thông tin tác giả